Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review
Posted on 2019-07-31 - 04:01
Abstract Background Primary retroperitoneal serous adenocarcinoma (PRSA) is an extremely uncommon malignancy exclusively reported in females. Due to the rarity of the disease, it is difficult to establish a standardized treatment. Case presentation We describe a unique case of PRSA in a 71-year-old male who presented with right-sided lower back pain and numbness. Magnetic resonance imaging identified a mass invading the adjacent psoas muscle and twelfth rib. Tissue biopsy confirmed poorly differentiated PRSA. Patient was initially treated with neoadjuvant carboplatin and paclitaxel chemotherapy regimen. This resulted in complete radiological resolution of the tumor. However, 12 weeks later, rapid recurrence was noted on follow-up CT scan. The patient was then treated with external radiotherapy with concurrent nivolumab, an anti-PD-1 antibody. The patient displayed a positive response to treatment with reduction in primary tumor and metastases and had a sustained disease control. Conclusion Treatment with radiotherapy in combination with anti-PD-1 antibody could be an effective modality of management for PRSA.
CITE THIS COLLECTION
Chae, Young; Saleem, Naira; Roh, Yoonhwan; Bilal, Haris; Viveiros, Pedro; Sukhadia, Bhoomika; et al. (2019). Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.4601576.v1
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics

AUTHORS (9)
YC
Young Chae
NS
Naira Saleem
YR
Yoonhwan Roh
HB
Haris Bilal
PV
Pedro Viveiros
BS
Bhoomika Sukhadia
XL
Xiaoqi Lin
MS
Muhammad Sheikh
LP
Lee Park